inhibitor compound

A technology of compound, alkyl, applied in the field of compound of spindle checkpoint function

Active Publication Date: 2019-07-05
CANCER RES TECH LTD
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This observation has led to the hypothesis that inhibition of Mps1 could have therapeutic benefit

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • inhibitor compound
  • inhibitor compound
  • inhibitor compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0881] (4-((5-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)isoquinolin-3-yl)amino)-3-methoxyphenyl )(3-methoxyazetidin-1-yl)methanone

[0882]

[0883] method 1

[0884] Make 2-(4-(3-chloroisoquinolin-5-yl)-1H-pyrazol-1-yl)-N,N-dimethylethylamine (preparation 1, 10mg, 0.033mmol), (4 -Amino-3-methoxyphenyl)(3-methoxyazetidin-1-yl)methanone (Formulation 28, 15.7 mg, 0.066 mmol), xantphos (11.5 mg, 0.02 mmol), Pd 2 (dba) 3 (3mg, 0.003mmol) and Cs 2 CO 3 (87 mg, 0.27 mmol) in toluene / DMF (3 / 1 mL) was stirred at 160 °C for 2 hours under microwave irradiation. The reaction mixture was filtered, diluted with NaCl solution and extracted with EtOAc. The organic layer was washed with 2M NH 3 Purified on an SCX-2 column eluting with / MeOH and concentrated in vacuo. The residue was purified by Biotage silica gel column chromatography eluting with 0-4% MeOH in EtOAc, followed by preparative HPLC to afford the title compound (5 mg, 30%).

[0885] 1 H NMR (500MHz, CDCl 3 ):δ9.07...

Embodiment 19

[0902] (3-methoxy-4-((5-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)isoquinolin-3-yl)amino)phenyl )(3-methoxyazetidin-1-yl)methanone

[0903]

[0904] To (3-methoxy-4-((5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)isoquinolin-3-yl)amino)phenyl)(3 A solution of -methoxyazetidin-1-yl)methanone (Example 20, 18 mg, 0.035 mmol) in DCM / MeOH (4 / 2 mL) was added with acetic acid (2.5 μL, 0.044 mmol) and aqueous formaldehyde solution (38% w / w, 6.0 μL, 0.073 mmol), followed by sodium triacetoxyborohydride (11.2 mg, 0.053 mmol). The reaction mixture was stirred at room temperature for 1 hour. The solvent was removed and the residue was washed with 2M NH 3 Purification by SCX-2 column eluting with / MeOH afforded the title compound (17 mg, 92%) as a yellow oil.

[0905] 1 H NMR (500MHz, CDCl 3 ): δ9.05(d, J=0.9Hz, 1H), 8.01(d, J=8.3Hz, 1H), 7.82(dt, J=8.3, 1.1Hz, 1H), 7.78(d, J=0.8Hz ,1H),7.69(d,J=0.8Hz,1H),7.54(dd,J=7.1,1.2Hz,1H),7.49(t,J=1.0Hz,1H),7.40-7.32(m,3H) ,7.20(dd,J=8.4,1.9Hz,...

Embodiment 20

[0909] (3-methoxy-4-((5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)isoquinolin-3-yl)amino)phenyl)(3- Methoxyazetidin-1-yl)methanone

[0910]

[0911] 4-(4-(3-((2-methoxy-4-(3-methoxyazetidine-1-carbonyl)phenyl)-amino)isoquinoline-5 -yl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester (Example 3, 23 mg, 0.038 mmol) in DCM (8 mL) was added TFA (0.5 mL). The reaction was stirred at room temperature for 16 hours. The solvent was removed in vacuo and the residue was washed with 2M NH 3 Purification by SCX-2 column eluting with / MeOH afforded the title compound (19 mg, 98%) as a yellow oil.

[0912] 1 H NMR (500MHz, CDCl 3 ):δ9.05(d,J=0.9Hz,1H),8.00(d,J=8.3Hz,1H),7.81(d,J=8.1Hz,1H),7.77(s,1H),7.69(s ,1H),7.54(dd,J=7.1,1.3Hz,1H),7.50(s,1H),7.40-7.30(m,3H),7.20(dd,J=8.3,1.9Hz,1H),4.55- 4.35(m,2H),4.35-4.30(m,1H),4.29-4.20(m,2H),4.15-4.05(m,1H),3.96(s,3H),3.33(s,3H),3.32- 3.27 (m, 2H), 2.87-2.78 (m, 2H), 2.30-2.22 (m, 2H), 2.04-1.92 (m, 2H).

[0913] LCMS (ESI) Rt = ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to compounds of formula (I), wherein R, R, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Mps1 kinase directly or indirectly via interaction with the single spindle 1 (Mps1, also known as TTK) kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and / or prevention of proliferative diseases such as cancer. The invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising these compounds.

Description

[0001] introduction [0002] The present invention relates to compounds that directly or indirectly inhibit the spindle checkpoint function of Mps1 kinase via interaction with the monopolar spindle 1 (Mps1, also known as TTK) kinase itself. In particular, the present invention relates to compounds useful as therapeutic agents for the treatment and / or prevention of proliferative diseases such as cancer. The invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising these compounds. [0003] Background of the invention [0004] Cancer arises from uncontrolled and unregulated cell proliferation. Precisely what causes cells to become malignant and proliferate in an uncontrolled and unregulated manner has been the focus of intense research in recent decades. Such research has led to the targeting of surveillance mechanisms (such as those responsible for regulating the cell cycle) with anticancer agents. For example, p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D401/14C07D413/14C07D401/04C07D405/04C07D471/04C07D519/00A61P35/00A61K31/4725A61K31/4375A61K31/519
CPCC07D401/04C07D401/14C07D405/04C07D413/14C07D471/04C07D519/00A61K31/519A61P35/00A61P43/00A61K31/4375A61K31/4725
Inventor 斯文·赫尔德J·布拉格萨瓦德·索兰基汉纳·伍德沃塞巴斯蒂安·诺德V·巴韦特西亚斯彼得·希德瑞克保罗·伊诺森蒂贵-明·J·张布特斯·阿特什
Owner CANCER RES TECH LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap